BioInvent’s Latest NHL Data to ASH Show Increased and Sustained Responses to BI-1206 in Relapsed Patients

  • Objective response rate (ORR) 67% and disease control rate (DCR) 78% in follicular lymphoma
  • Complete responses beyond 18, 24 and 36 months

LUND, SWEDEN / ACCESSWIRE / December 11, 2021 / BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotechnology company focused on the discovery and development of novel, first-class immunomodulatory antibodies for cancer immunotherapy, today announces updated interim data positive results of its novel anti-FcyRIIB BI-1206 antibody which shows increased response levels and sustained complete responses. The data represents the status – through early November 2021 – of the company’s Phase 1 / 2a clinical trial of BI-1206 in combination with rituximab (anti-CD20 monoclonal antibody) in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (NHL). They are published today in a poster at the 63rd Annual Meeting and Exhibition of the American Society of Hematology (ASH 2021).

The ASH 2021 poster shows that BI-1206 in combination with rituximab provided an objective response rate (ORR) of 54%, with three complete responses and four partial responses in 13 patients assessed for therapeutic benefit for all three indications ( Mantle cell lymphoma, Marginal zonal lymphoma and follicular lymphoma) included in the clinical study. Treatment stabilized the disease in an additional patient, resulting in a disease control rate of 62% (8 out of 13 patients).

When viewed on its own, the response rate for follicular lymphoma is particularly impressive: of nine evaluable patients, three developed CR, three developed RP, and one patient had SD by the cut-off date, resulting in a 67% TRG and 78% DCR. Previous treatments with rituximab without BI-1206 had failed in these patients, before entering the trial, all patients had relapsed on previous lines of treatment containing rituximab.

All complete responses were maintained for prolonged periods, with the longest complete response exceeding 36 months. In two additional patients, complete responses lasted beyond 12 and 24 months after stopping treatment.

“The current data are very encouraging and already show the benefit of BI-1206 in saving rituximab treatment in advanced NHL. Without BI-1206, rituximab did not work well in these patients. Based on our in-depth understanding of the immune mechanisms involved, these data indicate that BI-1206 not only restores the anti-tumor response, but does so safely and on a sustained basis in many patients, particularly in follicular lymphoma. . Adjusting the dosage regimen of BI-1206 may lead to further improvements. look forward to discussing all these aspects with investors during our next KOL call on December 17th ”, said Martin Welschof, PhD, CEO of BioInvent.

BioInvent will host a Key Opinion Leader (KOL) webinar on BI-1206 with Michael Wang, MD, of the MD Anderson Cancer Center, who will discuss the current landscape of NHL treatment and unmet medical needs. Senior management will discuss the data presented at ASH 2021 and the first data from the Phase 1 / 2a study of BI-1206 in combination with pembrolizumab for the treatment of solid tumors. The webinar will take place on Friday, December 17, 2021 at 1:00 p.m. ET / 7:00 p.m. CET.

To register for the webinar, please click here .

BI-1206 is BioInvent’s lead drug candidate and is currently in two Phase 1/2 trials. One is evaluating the BI-1206 combination with rituximab for the treatment of non-Hodgkin lymphoma; and the other is evaluating BI-1206 in combination with Keytruda® anti-PD1 therapy (pembrolizumab) in solid tumors. BI-1206 has also received approval to start clinical trials in China.

Since October 2020, BioInvent has entered into a licensing agreement with CASI Pharmaceuticals for China, including Hong Kong, Macao and Taiwan. Under the terms of the agreement, BioInvent and CASI will develop BI-1206 in hematologic and solid cancers, with CASI responsible for commercialization in China and associated markets.

ASH 2021 will take place December 11-14, 2021 at the Georgia World Congress Center – Atlanta, GA, and virtually. BioInvent’s poster is titled “Phase 1 / 2a clinical trial of BI-1206, a monoclonal antibody against FcyRIIB, in combination with rituximab in subjects with indolent B-cell non-Hodgkin lymphoma who have relapsed or are refractory to rituximab ”. The poster premieres today, December 11 at 5:30 p.m. ET (11:30 p.m. CET).

About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotechnology company that discovers and develops novel, first-class immunomodulatory antibodies for the treatment of cancer, with currently three drug candidates in four ongoing clinical programs in Phase 1 / 2 trials for the treatment of hematologic cancer and solid tumors, respectively, and a fifth program which has just started clinical development. The Company’s patented and validated FIRST â„¢ technology platform simultaneously identifies targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s clinical development pipeline or for licensing and partnerships additional.

The Company generates revenue from research collaborations and licensing agreements with several leading pharmaceutical companies, as well as from the production of antibodies for third parties in the Company’s fully integrated manufacturing unit. More information is available at .

For more information, please contact:
Cecilia Hofvander
Senior Director of Investor Relations
+46 (0) 46 286 85 50
[email protected]

BioInvent International AB (published)
Reg. Organization number: 556 537-7263
Visiting address: Ideongatan 1
Postal address: 223 70 LUND
Telephone: +46 (0) 46 286 85 50

Disclaimer – BioInvent
The press release contains statements about the future, consisting of subjective assumptions and predictions for future scenarios. Predictions for the future only apply when they are made and are, by their very nature, like research and development in the field of biotechnology, associated with risks and uncertainties. With this in mind, the actual result may deviate significantly from the scenarios described in this press release.

This information is information that BioInvent International is obliged to make public in accordance with the EU Market Abuse Regulation. The information has been submitted for publication, through the contact persons indicated above, on 2021-12-11 at 11:30 p.m. CET.

See the source version on